The 10 Best Stocks to Buy to Play Tech, Energy, and Biotech

Each week our experts dish out the best stocks to buy now for our Money Morning Members - all for free.

Money Morning Defense & Tech Specialist Michael A. Robinson recommends two favorites that will play off huge tech trends in the making.

Resource Specialist Peter Krauth has a surefire way to play oil without buying an oil stock.

And Chief Investment Strategist Keith Fitz-Gerald shared three stocks ready to soar from streaming television.

You can find all of last week's picks here in our newest list of the best stocks to buy now.

Money Morning's Best Stocks to Buy Now

  • We're living in the age of original content. Netflix (Nasdaq: NFLX) and Amazon (Nasdaq: AMZN) dominate the market with hit shows like "House of Cards" and "Transparent." Netflix gained two million paying subscribers alone by the end of Q1 2013. That was enough revenue to pay back the cost of "House of Cards" in just three months. Amazon's Q2 2014 earnings report showed a 24% increase in revenue year over year. The two streaming giants are investing millions to steal a huge piece of the market share. But - what will surprise many investors - they're not the best picks to profit from this trend. Money Morning Chief Investment Strategist Keith Fitz-Gerald knows of three tech companies that help move the content itself - one of which has jumped 19% in the last two months...
  • [epom key="ddec3ef33420ef7c9964a4695c349764" redirect="" sourceid="" imported="false"]

    Antibiotic-resistant bacteria are becoming a national health crisis. The Center for Disease Control and Prevention (CDC) reports that these microorganisms kill 23,000 people and make two million people sick each year. The first company to treat this problem is going to be handsomely rewarded with profit. Money Morning Biotech Investing Specialist Ernie Tremblay discussed four companies developing drugs to treat these infections. One company's stock has seen a 200% increase over the past five years. And it's destined to keep soaring. Tremblay discusses these four pharma firms closest to wiping out the "nightmare bacteria" - and getting huge profits...

Bonus Content: There are fears of a looming market meltdown. The main indicator behind that is a "total margin debt" caused by investors borrowing heavily from their brokerage accounts. The debt has mounted to $457 billion. But Chief Investment Strategist Keith Fitz-Gerald says it's not what it seems...